| Ticker Symbol: | BPAX |
|---|---|
| Exchange: | NASD |
| Contact Info: | 111 Barclay Boulevard Lincolnshire IL 60069 847 478-0500 |
| CEO/President: | Stephen M. Simes |
| Industry: | Medical - Biomedical / Standard Industry Code: 2836 |
| Description: | Biosante Pharmaceutical is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante also is developing its nanoparticulate-based platform technology for novel vaccines, vaccine adjuvants and drug delivery systems. |
| Shares Outstanding: | 26,800 (000) | Market Value: | 54,090 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 10.50% | Number of Inst.Shareholders: | 29.10% |
| Last Quarter Sales: | 0.02 ($Mil.) | Last Quarter Net Income: | -6.00 ($Mil.) |
| Last Quarter EPS: | -0.22 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -0.41 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN | +12.60 | 58.23 | |
| GILEAD SCIENCES | -1.00 | 46.92 | |
| CELGENE CP | -10.00 | 58.86 | |
| BIOGEN IDEC INC | -31.90 | 43.52 | |
| AMYLIN PHARMA I | -85.70 | 6.41 |
